|Mr. Stephen P. Carey||Sr. VP & CFO||719.68k||N/A||1971|
|Mr. James G. Marken||Sr. VP of Operations & Product Devel.||608.59k||N/A||1963|
|Mr. Nikhil Lalwani||Pres, CEO & Director||N/A||N/A||1978|
|Mr. Christopher K. Mutz||Chief Commercial Officer & Head of Rare Diseases||N/A||N/A||1971|
|Mr. Ori Gutwerg||Sr. VP of Generics||N/A||N/A||1974|
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
ANI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 10.